Geoffrey Attardo first tried Prozac to treat his depression when he was doing postdoctoral research at Yale School of Public Health and was feeling the pressures of a new job in academia. Soon after he started, the colors around him seemed brighter, he had enough motivation to begin exercising more, and he felt hopeful for the first time in a long while. But about five months into the treatment, colors started dulling again and his energy waned. Increasing the dose didnt help.
He eventually switched to a similar antidepressant called Zoloft and has been on it for about 20 years, though it makes him emotionally numb and never completely got rid of the depression. It takes the edge off and keeps you from completely breaking down, he said, but its not really a great way to live.
Then this year, Attardo, who is 49, tried a new treatment for depression ketamine a drug long used as an anesthetic and that works through a different pathway in the brain than the traditional drugs hed taken. A few days after one of his first ketamine infusions, he found himself awake at 9 a.m., a time he usually slept long past, with much more energy than usual.
advertisement
Patient responses like Attardos, after years of unsuccessful treatment with standard drugs, are spurring a gradual and, some would say, overdue shift in psychiatry toward a new way of thinking about depression, its causes, and therapies. The professions long embrace of the monoamine hypothesis the idea that depression primarily results from abnormal levels of neurotransmitter chemicals in the brain and that drugs can restore the proper balance is giving way to a more complex understanding and alternative treatments, from ketamine to psychedelics to magnetic stimulation.
The stubbornly high, and steadily increasing, rate of suicides in the U.S.is one factor driving the shift. In April, the National Institute of Mental Health (NIMH) awarded eight grants to test new ways to reduce suicidal thoughts and behaviors in a fast-acting manner, including ketamine and using magnets to activate parts of the brain.
advertisement
Overall, an unofficial estimate shows the agencys funding for research involving novel antidepressants roughly doubled from $34.3 million in the 2007 fiscal year to $68.5 million in FY 2020, based on a search of the National Institutes of Health RePORTER database. A search for transcranial magnetic stimulation for depression reveals an estimated ninefold increase to $21.4 million over the same period.
Nolan Williams, a psychiatrist and neurologist at Stanford University, received one of the new grants as well as another from the NIMH to study magnetic stimulation in treatment-resistant depression. He said there is a push in the field to to think beyond the typical view of depression, and consider new treatments. Were enhancing [the monoamine] view to have a multilevel understanding of the problem, he said. Its about incorporating it into a deeper, more dynamic understanding [of depression].
NIMH Director Joshua Gordon told STAT the agency recognizes that new treatments for depression are needed and that it is funding research to explore the underlying biology beyond the monoamine hypothesis. When it comes to understanding depression, there are fewer and fewer questions of importance with regard to the monoamine systems, he said. He noted that in addition to federal funding, many startups and small companies are pursuing new treatments for depression.
Currently, almost all patients with depression are first treated with medications called selective serotonin reuptake inhibitors, a class of drugs that includes both Zoloft and Prozac. They increase the amount of the neurotransmitter serotonin in the brain, which controls mood, emotions, and cognition. Serotonin and two other neurotransmitters targeted by some antidepressants, norepinephrine and dopamine, are called monoamines because they contain one chemical group called an amine.
The entire thinking of the approach to treating depression is pretty much confined in that little box, said Lisa Harding, a psychiatrist at the Yale School of Medicine.
The monoamine hypothesis came about by serendipity. In the 1960s, doctors found that certain drugs, like iproniazid that was used to treat tuberculosis, had an unintended side effect: They messed with the levels of monoamine neurotransmitters and affected patients mood. The explanation for mental health disorders had previously eluded psychiatrists, so they were overjoyed to have a lead to follow.
The theories arose because of the actions of the drugs, said Phil Cowen, professor of psychopharmacology at University of Oxford who studies depression. In retrospect, its simplistic, but there wasnt really much else to go on.
Soon, clinicians realized that some observations didnt mesh with the hypothesis. Antidepressant drugs took weeks to improve the symptoms of depression, suggesting that the drugs may not be working through neurotransmitters exclusively. Then, psychiatrists found that many people, like Attardo, did not respond to monoamine antidepressants. About 1 out of every 3 patients with depression is diagnosed with treatment-resistant depression, meaning at least two antidepressants failed to improve their symptoms.
Even with these contradictions, doctors faithfully stuck by the hypothesis as the central dogma. The field got stuck in a cul-de-sac of just looking at [the same drugs], said Cowen.
Then a study done by researchers at Yale University in 2000 found that ketamine rapidly improved depression symptoms in seven patients. Although it was a small study, it opened the door for researchers to explore other potential treatments for depression.
Weve now got a completely different option for the treatment-resistant group, said Susannah Murphy, researcher at the University of Oxford who studies how to improve treatments for depression. The finding emboldened researchers to explore other drug targets and develop different therapies, she added: It put a lot more confidence back in new treatments.
Researchers are now exploring those new treatments and, in parallel, are seeking to advance the biological understanding of mental health disorders. In 2019, the FDA approved Spravato, a nasal spray of a version of ketamine called esketamine, for the treatment of adults with treatment-resistant depression. Studies have found that ketamine works through receptors for another neurotransmitter, glutamate, which is also dysregulated in depression. Glutamate and its receptors underlie a process called synaptic plasticity, in which brain connections strengthen or weaken. This supports the idea that changes in synaptic plasticity underlie depression and by targeting glutamate, ketamine could be reversing those changes.
Along with ketamine, other psychedelics, like psilocybin, have emerged as candidates for treatment-resistant depression. A small study published in the New England Journal of Medicine in April showed that psilocybin was as effective as a common antidepressant drug.
The psychedelic market is seen as so potentially lucrative that half a dozen companies in that space have gone public this year. Cybin, which has a psilocybin formulation in a Phase 2 clinical trial for major depression, started selling shares on the New York Stock Exchange last week, and five other psychedelics companies are already listed on the Nasdaq.
Psychedelics like psilocybin mostly activate receptors for serotonin, similar to the typical antidepressants. But studies show that psilocybin also can change levels of glutamate, suggesting it, too, involves synaptic plasticity.
Many clinicians and researchers say the field should move beyond a focus on neurotransmitters and look at activating entire neural circuits in the brain, networks of interconnected neurons that perform specific functions. Theres not one neurotransmitter, not one neural site where things go wrong, its some system-level dysfunction in the brain, said Cowen. A recent study analyzed patients with depression who underwent deep brain stimulation, in which electrodes are implanted to pass current through specific brain areas, or transcranial magnetic stimulation, which is a noninvasive form of stimulation. By looking at whether patients symptoms improved or worsened, researchers identified a brain circuit that includes the dorsolateral prefrontal cortex, an area that controls emotion processing and is impaired in patients with depression, that could be targeted to treat depression.
Understanding and treating depression could even go beyond the brain, as immune molecules such as cytokines that control inflammation could also be considered potential treatment targets. One analysis found that patients with depression had different levels of neuroinflammatory molecules in the blood. Other clues come from observing patients treated with medications that target inflammation for other conditions. Such studies found that patients treated with drugs that suppress immune activity, like those that target the molecule IL-6, had reduced depressive symptoms.
While the paradigms surrounding psychiatry seem to be shifting, new drugs and treatments still have a long road to approval and widespread use. The drug development pipeline has been particularly fruitless for psychiatry, which has a 6.2% likelihood of getting a drug from Phase 1 clinical trials to approval, as compared to infectious diseases treatments that have about 20% likelihood of approval.
Even if new treatments are approved, patients could encounter obstacles in accessing them, especially populations that already have poor access to mental health care due to high rates of poverty and lack of insurance, experts say. Many of the novel therapies are technically challenging to administer and require specialized facilities with trained professional staff. And many psychedelics are still classified as Schedule I drugs, as illegal as street drugs like heroin. Some, like ketamine, can be abused, and the long-term effects of chronic use of psychedelics are not clear, said Gerard Sanacora, psychiatrist and director of the Yale Depression Research Program.
A number of states have moved to relax laws governing use of psychedelics. In November 2020, Oregon became the first state to decriminalize possession and legalize therapeutic use of psilocybin, the active ingredient in magic mushrooms, and California may soon be next. In March of this year, a law decriminalizing magic mushrooms, ayahuasca, and mescaline went into effect in Washington, D.C. Recently, Rep. Alexandria Ocasio-Cortez (D-N.Y.) proposed an amendment to allow research into the therapeutic potential of Schedule I drugs like psilocybin and ecstasy.
The research and law changes are giving many patients a reason for optimism. Attardo is eager to try psilocybin, which data suggest could have a longer-lasting therapeutic effect than ketamine, whose benefits last just a few days for him. Just knowing that his depression can disappear, like when he is taking ketamine or during those first few months on Prozac, gives him hope: Im not trapped forever.
Go here to see the original:
Researchers breaking away from the central dogma of depression - STAT - STAT
- Review: Tripping on Utopia Complicates the History of Psychedelics - AOL - March 16th, 2024 [March 16th, 2024]
- Psychedelics Are Going Mainstream. Investing in Them Hasn't. - The Wall Street Journal - January 7th, 2024 [January 7th, 2024]
- Another Study Shows African Psychedelic Plant Ibogaine Treats Traumatic Brain Injury in Vets With 'Dramatic' Results - Good News Network - January 7th, 2024 [January 7th, 2024]
- Massachusetts Lawmakers Will Be Forced To Consider Psychedelics Legalization Measure That Activists Petitioned ... - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA to begin researching psychedelics as treatment option for veterans - Government Executive - January 5th, 2024 [January 5th, 2024]
- VA Is Funding New Research On Psychedelics' Benefits For Veterans With PTSD And Depression - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA ramps up study of psychedelic to treat PTSD - The American Legion - January 5th, 2024 [January 5th, 2024]
- Scientists predict DMT trip from cardiac activity - Big Think - January 5th, 2024 [January 5th, 2024]
- If psychedelics heal, how do they do it? | Proceedings of the National Academy of Sciences - pnas.org - January 5th, 2024 [January 5th, 2024]
- Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential | Molecular ... - Nature.com - January 5th, 2024 [January 5th, 2024]
- U.S. Rep. Correa supports using psychedelics to treat veterans with PTSD - New Santa Ana - January 5th, 2024 [January 5th, 2024]
- DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Psychedelics for Psych Conditions Made Their Mark in 2023 - Medpage Today - January 5th, 2024 [January 5th, 2024]
- 2023: A Good Trip Around the Sun for Psychedelics - The National Law Review - January 5th, 2024 [January 5th, 2024]
- Understanding the Role of the FDA in Advancing Psychedelic Therapy - Medriva - January 5th, 2024 [January 5th, 2024]
- MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics - Psychedelic Alpha - January 5th, 2024 [January 5th, 2024]
- Closing the innovation gap: Advancing psychedelic therapy and medicines in EU mental health care - Open Access Government - January 5th, 2024 [January 5th, 2024]
- The Austin Chronic: SXSW Is High on Psychedelics, as Cannabis Programming Wanes - Austin Chronicle - January 5th, 2024 [January 5th, 2024]
- This Forgotten Psychedelic Could Revolutionize Traumatic Brain Injury Treatment - Inverse - January 5th, 2024 [January 5th, 2024]
- A 'milestone' for psychedelics: Pentagon directed to study alternative treatments for veterans - Washington Times - January 5th, 2024 [January 5th, 2024]
- Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here's What's Next - Singularity Hub - January 5th, 2024 [January 5th, 2024]
- The top 8 psychedelic books you need to read | GreenState - GreenState - January 5th, 2024 [January 5th, 2024]
- Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC - Green Market Report - January 5th, 2024 [January 5th, 2024]
- DEA Calls For Even More THC, Psilocybin And DMT To Be Produced For Research In 2024 - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Here's What You Missed in Cannabis, Psychedelics This Week - TipRanks.com - TipRanks - January 5th, 2024 [January 5th, 2024]
- You're not tripping: State and local leaders give psychedelics another chance - Route Fifty - December 22nd, 2023 [December 22nd, 2023]
- Are Consciousness-Expanding Psychedelics Like Psilocybin More Effective Than Prozac, Zoloft, Xanax, and Other ... - Nautilus - December 22nd, 2023 [December 22nd, 2023]
- RFK, Ramaswamy And Williamson Push Psychedelics Reform On Presidential Campaign Trail - Marijuana Moment - December 22nd, 2023 [December 22nd, 2023]
- Peyote is the darling of the psychedelics renaissance. Indigenous users say it co-opts a sacred way of life - The Guardian US - December 22nd, 2023 [December 22nd, 2023]
- USask researchers explore untold history of psychedelics - News - University of Saskatchewan - USask News - December 22nd, 2023 [December 22nd, 2023]
- California Governor Says Psychedelics Have 'Profound' Healing Potential, But He's Undecided On Legalization Bill As ... - Marijuana Moment - September 25th, 2023 [September 25th, 2023]
- As psychedelic-assisted therapy grows, so does interest from a new group: chaplains - NPR - September 25th, 2023 [September 25th, 2023]
- This Maine City Moves Unanimously On Decriminalizing Psychedelics: Focus On Public Health - Benzinga - September 25th, 2023 [September 25th, 2023]
- Tech Leaders Are Finding Balance Through Microdosing Psychedelics - The Dales Report - September 25th, 2023 [September 25th, 2023]
- Chronic Pain Can Be Treated by Psychedelics, Survey Suggests - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Insights Into the First Psychedelic-Assisted Therapy Guidelines With ... - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Living with long-term cancer is depressing. Texas doctors say psychedelics could help - The Hill - July 19th, 2023 [July 19th, 2023]
- Couples Are Doing MDMA and Ketamine Therapy To Save Their Relationships - VICE - July 19th, 2023 [July 19th, 2023]
- The Way People Are Using Psychedelics Is Changing Amid Reform ... - Marijuana Moment - July 19th, 2023 [July 19th, 2023]
- [WATCH] Turn on, tune in, legalise: Could psychedelics be next in ... - MaltaToday - July 19th, 2023 [July 19th, 2023]
- Will Psychedelics Be Rescheduled After FDA Approval? - Harris Bricken - July 19th, 2023 [July 19th, 2023]
- The Psychedelic Preparedness Scale: A Tool to Optimize Trip ... - Filter - July 19th, 2023 [July 19th, 2023]
- How to Test Psychedelics for Adulterants with Testing Kits - Psychedelic Spotlight - July 19th, 2023 [July 19th, 2023]
- Cannabis Science Conference to debut in Providence, R.I., with ... - GlobeNewswire - July 19th, 2023 [July 19th, 2023]
- New Speaker Rivas weighs in on psychedelics, housing and health care worker minimum wage - Yahoo News - July 19th, 2023 [July 19th, 2023]
- TDR's Top 5 Psychedelic Developments For The Week Of July 10 - The Dales Report - July 19th, 2023 [July 19th, 2023]
- Psychedelic Treatment with Psilocybin Relieves Major Depression, Study ... - February 20th, 2023 [February 20th, 2023]
- Johns Hopkins Launches Center For Psychedelic Research - February 20th, 2023 [February 20th, 2023]
- Psilocybin Treatment for Major Depression Effective for Up to a Year ... - February 20th, 2023 [February 20th, 2023]
- Inside the Johns Hopkins Psilocybin Playlist - Hopkins Medicine - February 20th, 2023 [February 20th, 2023]
- Research Story Tip: Psychedelic Drug Psilocybin Tamps Down Brains Ego ... - February 20th, 2023 [February 20th, 2023]
- Psychedelics: Risks, benefits, and more - Medical News Today - February 18th, 2023 [February 18th, 2023]
- Psychedelic Drug Effects, Side Effects & Dangers - January 25th, 2023 [January 25th, 2023]
- Psychedelics Decriminalization Project In Berkeley, Cal Includes ... - January 6th, 2023 [January 6th, 2023]
- Ancient mummified child was drugged with psychedelics before ritual ... - December 14th, 2022 [December 14th, 2022]
- The therapeutic potential of psychedelics - Science - December 14th, 2022 [December 14th, 2022]
- Changing Lives with Psychedelics: How Connecticut researchers are using magic mushrooms to help people overcome depression, OCD - WTNH.com - November 19th, 2022 [November 19th, 2022]
- Penis Envy Mushroom | Legal Psychedelics | Magic Mushroom - November 7th, 2022 [November 7th, 2022]
- Psychedelics. Discussing natural and synthetic friends. Science, News ... - November 5th, 2022 [November 5th, 2022]
- The Harms of Psychedelics Need to Be Put Into Context - WIRED - November 5th, 2022 [November 5th, 2022]
- Packers' Aaron Rodgers says psychedelics led to his back-to-back MVP ... - October 28th, 2022 [October 28th, 2022]
- With Promise of Legalization, Psychedelic Companies Joust Over Future Profits - The New York Times - October 25th, 2022 [October 25th, 2022]
- How do psychedelics work? This brain region may explain their effects - PBS - October 21st, 2022 [October 21st, 2022]
- Why is the American right suddenly so interested in psychedelic drugs? - The Guardian - October 19th, 2022 [October 19th, 2022]
- Can Psychedelics Cure? Science Is on the Verge of Finding Out - Newsweek - October 19th, 2022 [October 19th, 2022]
- Large national survey suggests that the use of psychedelics is not associated with lifetime cancer development - PsyPost - October 19th, 2022 [October 19th, 2022]
- This Pharma Company Just Scored Another Psychedelics Patent And Set Its Sights On 70 More - Small Pharma - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Made the Mushrooms Magic: Psychedelic Study Explores the Odd Evolution of Mind-Altering Fungi - The Debrief - October 19th, 2022 [October 19th, 2022]
- Psychedelics And Wellness: The Healing Company Buys PepsiCo-Backed Superfoods Company - (HLCO) - Benzinga - October 19th, 2022 [October 19th, 2022]
- What's on the Colorado ballot? Housing, psychedelics, school meals, alcohol, taxes and more | FOX31 Denver - FOX 31 Denver - October 19th, 2022 [October 19th, 2022]
- DoseConnect to Sponsor the Tech Stage at Wonderland Miami by Microdose - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Is Going on With Bright Minds (DRUG) Stock Today? - InvestorPlace - October 19th, 2022 [October 19th, 2022]
- Psychedelics May Ease Fear of Death and Dying - October 17th, 2022 [October 17th, 2022]
- TDR's Top 5 Psychedelic Developments For The Week Of October 10 - The Dales Report - October 17th, 2022 [October 17th, 2022]
- DEA Wants To Boost Production Of Cannabis & Psychedelics For Research In 2023 - Benzinga - October 17th, 2022 [October 17th, 2022]
- Talk set to explore psychedelics and mental health - Reading Today - October 17th, 2022 [October 17th, 2022]
- Silo Wellness Closes Acquisition of Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- How does psilocybin rewire the brain? - Open Access Government - October 17th, 2022 [October 17th, 2022]
- HYTN Awarded Controlled Drugs and Substances Dealers License Allowing for Production and Sale of Psilocybin - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- The Healing Company acquires leading superfoods business, Your Super, and lands $150M credit facility to expand community of brands - Yahoo Finance - October 17th, 2022 [October 17th, 2022]